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INTRODUCTION
Sickle cell anemia (SCA) is among the world’s most common
inherited anemias, and results in significant morbidity and early
mortality. SCA is most prevalent in sub-Saharan Africa, where
>250,000 affected babies are born annually, representing 1–2% of
newborns in some countries.[1–3] These astounding numbers may
even underestimate the true burden of disease within sub-Saharan
Africa, as accurate birth incidence rates areunknowndue to the lack of
systematic newborn screening (NBS) across the continent. The impact
of SCA upon child mortality in areas with high prevalence is likely
under-recognized, due to lack of NBS programs and accurate health
information systems to capture the deaths of children with SCA.[4]
In North America and Europe, each of which contributes only
1% of the global annual sickle cell births, SCA is a medical
condition with recognized impact upon both the quality and length
of affected lives. Effective identification through NBS is coupled
with simple early interventions (prophylactic penicillin, pneumo-
coccal immunization) and caregiver education (fever management,
spleen palpation), which together have drastically reduced the
morbidity and mortality associated with SCA in developed
countries.[5,6] The availability of disease-modifying treatments
(transfusions, hydroxyurea, and stem cell transplantation) in
developed countries has also improved the medical outcomes of
patients with SCA.[5–9] In contrast, without NBS for early
identification, and little access to preventive interventions or
disease-modifying therapies, most babies in Africa with SCA die
of acute anemia or infection within the first years of life, often
without a diagnosis.[10–14] Due to limited availability and use
of hydroxyurea or other proven disease-modifying therapies, a
number of herbal, traditional, and perhaps unsafe treatments and
procedures are commonly used to treat SCA across Africa.
In 2010, WHO recognized SCA as a significant health problem
for sub-Saharan Africa and recommended screening and treatment
programs.[2] Several countries have begun pilot NBS programs that
document the feasibility of this approach.[15–17] Such screening
programs can significantly reduce the early mortality of SCA,
particularly if they are linked to penicillin and pneumococcal
immunization, but will not treat the underlying disease. In fact,
improved identification of SCAwill increase its perceived “burden”
in these countries, as children diagnosed by screening will survive
early childhood and suffer severe medical complications.[18] For
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Background. Sickle cell anemia (SCA) is an inherited hematolog-
ical disorder that causes a large but neglected global health burden,
particularly in Africa. Hydroxyurea represents the only available
disease-modifying therapy for SCA, and has proven safety and
efficacy in high-resource countries. In sub-Saharan Africa, there is
minimal use of hydroxyurea, due to lack of data, absence of
evidence-based guidelines, and inexperience among healthcare
providers. Procedure. A partnership was established between
investigators in North America and sub-Saharan Africa, to develop
a prospective multicenter research protocol designed to provide data
on the safety, feasibility, and benefits of hydroxyurea for children
with SCA. Results. The Realizing Effectiveness Across Continents
with Hydroxyurea (REACH, ClinicalTrials.gov NCT01966731)
trial is a prospective, phase I/II open-label dose escalation study
of hydroxyurea that will treat a total of 600 children age 1–10
years with SCA: 150 at each of four different clinical sites within
sub-Saharan Africa (Angola, Democratic Republic of Congo,
Kenya, and Uganda). The primary study endpoint will be severe
hematological toxicities that occur during the fixed-dose treatment
phase. REACH has an adaptive statistical design that allows for
careful assessment of toxicities to accurately identify a safe
hydroxyurea dose. Conclusions. REACH will provide data that
address critical gaps in knowledge for the treatment of SCA in sub-
Saharan Africa. By developing local expertise with the use of
hydroxyurea and helping to establish treatment guidelines, the
REACH trial results will have the potential to transform care for
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this reason, treatment options must be considered as countries begin
to develop national sickle cell strategies.
Hydroxyurea, an oral medication with a well-established safety
and efficacy profile in developed countries, is the most plausible
therapeutic option for the majority of affected patients living in
resource-poor countries, where access and safety of other potential
therapeutic options, primarily chronic blood transfusions or stem
cell transplantation, are currently not affordable or realistic options.
We now describe a novel partnership between investigators in
North America and Africa, bolstered by industry-supported drug
donation, which led to a consensus prospective research protocol
that will address the current knowledge gaps regarding the safe
introduction of hydroxyurea into sub-Saharan Africa for children
with SCA.
METHODS
Identifying the Knowledge Gaps
Hydroxyurea is a once-daily oral medication with over 30 years
of evidence, demonstrating safety and efficacy for both adults and
children with SCA.[19] Hydroxyurea capsules are rapidly absorbed
and excreted with a well-described pharmacokinetic profile, and
their contents are easily dissolved in a variety of liquids.[20,21] The
mechanisms by which hydroxyurea provides benefits for patients
with SCA are multi-factorial, but the most important and easily
measured benefit is fetal hemoglobin (HbF) induction, which is
associated with clear laboratory and clinical benefits.[22] Several
studies in the United States and Europe have demonstrated that
hydroxyurea treatment of SCA reduces the frequency and severity
of many acute clinical complications and also reduces mortality
for both adults and children.[23–30] After years of accumulated
evidence, hydroxyurea has become widely accepted as a safe and
effective disease-modifying therapy for both adults and children
with SCA. New guidelines from the National Heart, Lung, and
Blood Institute (NHLBI) recommend that hydroxyurea be offered
to all children with SCA beginning at 9 months of age, regardless
of clinical symptoms.[31]
Despite the large body of evidence, hydroxyurea is rarely
used in low-resource settings, particularly in sub-Saharan Africa,
where the burden of SCA is greatest. Hydroxyurea use is limited
in these settings for a number of reasons, including the following
three critical knowledge gaps: (1) lack of data on the magnitude and
impact of SCA in low-resource settings; (2) absence of treatment
guidelines based on prospective evidence demonstrating feasibility,
safety, and benefits in low-resource settings; and (3) inexperience
regarding dosing and toxicities among healthcare providers.
Additional barriers to hydroxyurea usage relate to drug availability
and cost of treatment and laboratory monitoring.[32]
Rationale for a Clinical Trial in Africa
At the 2010 Global Congress on Sickle Cell Disease in Accra,
Ghana and through the Global Sickle Cell Disease Network
(GSCDN, http://www.globalsicklecelldisease.org), the need for
a prospective clinical trial with hydroxyurea was identified,
specifically one focusing on safety data, appropriate dosing, and
the feasibility of periodic visits with laboratory monitoring in
limited resource settings.[33] Hydroxyurea is known to cause mild
and reversible myelosuppression with predictable cytopenias that
are used to determine the maximum tolerated dose (MTD).[22–24]
In developed countries, these dose-dependent cytopenias have not
resulted in serious infections or other significant clinical events.
[22–29] However, it is unclear whether nutritional deficiencies
(such as vitamin deficiencies and severe acute or chronic
malnutrition) and the unique infectious comorbidities in sub-
Saharan African children, including malaria and other parasitic
diseases,[34] helminthic infections and suboptimal vaccination
against important bacterial pathogens,[12] will exacerbate these
marrow-toxic effects of hydroxyurea. Doses commonly and safely
used in children with SCA living in high-resource settings may not
be safe in this environment. A prospective research trial is needed to
provide these critical data.
Designing the Hydroxyurea Trial
The realizing effectiveness across continents with hydroxyurea
(REACH, ClinicalTrials.gov identifier NCT01966731) trial was
designed to answer a critical set of questions about the use of
hydroxyurea for children with SCA in sub-Saharan Africa. In this
unique setting, is daily hydroxyurea treatment with monthly
laboratory monitoring feasible? Will treatment be safe? Will there
be clinical benefits? Can the dose be escalated and maintained with
only periodic laboratory monitoring? Before hydroxyurea can be
introduced widely into Africa, pilot data are needed to assess the
feasibility, safety, and benefits in a limited-resource setting.
The study design process involved multiple discussions among
the international team of investigators. One critical discussion point
related to the relative merits of a placebo-controlled versus open-
label trial to determine whether hydroxyurea is safe and effective in
this setting, recognizing that hydroxyurea has not been used
extensively in sub-Saharan Africa. Ultimately, a placebo-controlled
study design lacked support from both African and North American
investigators. The BABY HUG study clearly demonstrated the
clinical benefits of hydroxyurea compared to placebo in a young age
group,[24] so another placebo-controlled study of hydroxyurea
seemed unnecessary and potentially unethical. From the viewpoint
of the African investigators, despite recognizing that local
comorbidities might affect the safety of hydroxyurea, it was agreed
that hydroxyurea therapy should result in similar laboratory and
clinical benefits, so placebo would only deprive children of a
potentially life-saving drug.
The objectives of the REACH study therefore focus on the
feasibility and safety of open-label hydroxyurea in this patient
population, while also providing preliminary data on its benefits.
Beyond identifying a safe starting dose, REACH should determine
whether dose escalation to MTD and sustained hydroxyurea
therapy are both feasible and safe. Although a true efficacy trial
was not appropriate, data should be collected with regard to the
laboratory and clinical benefits of hydroxyurea treatment. In
addition to these clinical objectives, an important objective of
REACH is to evaluate the economic cost of providing hydroxyurea
therapy (including associated monitoring) at each of the clinical
sites. These economic data will be important as strategies are
designed and implemented to increase access to hydroxyurea in
these low-resource countries. The short-term goal of REACH is to
obtain critical pilot data regarding the feasibility, safety, and
benefits of hydroxyurea for children with SCA at four distinct
research settings in Africa. Although hydroxyurea is included in the
WHO Model List of Essential Medications for Children[35]
hydroxyurea remains widely unavailable or too expensive in most
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African settings. Based on the pilot information gained in the
REACH study, the long-term goal is to work with governments to
make hydroxyurea more widely available for children with SCA in
Africa.
Selecting the Clinical Sites
REACH sites were selected after a careful screening process with
the assistance of the GSCDN. This screening process included
completion of a detailed survey requesting information about their
site,which focused on their readiness to conduct high-quality clinical
research, as well as both teleconferences and site visits. Prior to
official selection as a REACH clinical site, laboratory capacity was
carefully evaluated, including the ability to reliably perform
complete blood counts and reticulocyte counts (using an automated
hematology analyzer), the ability to obtain quantitative fetal
hemoglobin levels (by HPLC or capillary electrophoresis), and the
ability to maintain adequate quality assurance within the laboratory.
Each clinical site has one physician as the local Lead Investigator
with several supporting physicians ormedical officers as a part of the
study team to provide clinical care for the study participants. Figure 1
provides a summary of the four selected REACH clinical sites.
Securing the Drug Supply
The hydroxyurea drug supply for REACH will be supplied
through a donation by the Bristol-Myers Squibb (BMS) Foundation,
the philanthropic arm of the large pharmaceutical company. This
donation was provided through an investigator-initiated proposal
and BMS retains no oversight of the study conduct or results, except
for required safety monitoring. Hydroxyurea will be supplied from
the BMS commercial supply (200, 300, 400, and 500mg capsules)
and shipped directly to the clinical sites.
Management of International Data
Withmultiple clinical sites across sub-Saharan Africa, a unifying
electronic data capture system was required to serve as a reliable
data management system for the REACH study. The Research
Electronic Data Capture (REDCapTM) system is a secure, web-based
data capture system used in over 70 countries. Separate REDCap
environments have been developed in English, French, and
Portuguese to accommodate the local languages at each clinical site.
RESULTS
Study Overview
REACH is a prospective, phase I/II open-label dose escalation
trial of hydroxyurea for children with confirmed SCA, between
12 months and 10 years of age, that is being conducted at four
clinical sites in sub-Saharan Africa. The sites reflect an intentional
range of diversity in clinical resources, research experience,
and number and types of patients, which will help the results
be considered more generalizable for children with SCA across
central Africa. The multicenter nature of REACH is an important
component of the study design, as extrapolation of results from
single center clinical trials has limitations.[36]
Recruitment and Enrollment
The clinics at the local sites have large populations of children
with SCA, with most seeing hundreds or even a thousand new
patients annually. All patients will be recruited from these existing
centers. The goal is to enroll and treat 150 participants at each site
for a total of 600 children. Table I outlines the inclusion and
exclusion criteria, which are intended to allow enrollment of most
affected children, while minimizing potentially unsafe exposure of
hydroxyurea to severely malnourished or chronically ill patients.
Fig. 1. REACH Clinical Sites. After a careful screening and selection
process, four unique sites across sub-Saharan Africa with large sickle
cell patient populations were selected as the clinical sites for the
REACH trial.
TABLE I. REACH Inclusion and Exclusion Criteria
Inclusion criteria
Diagnosis of sickle cell anemia (typically HbSS confirmed by local
lab techniques)
Age 1.00–9.99 years, inclusive, at time of enrollment
Weight of at least 10.0 kg at the time of enrollment
Parent/guardian willing/able to provide written informed consent
Willingness to comply with all study-related treatments and
evaluations
Exclusion criteria
Known medical condition making participation ill-advised
Acute or chronic severe malnutrition as defined by WHO
(weight-for-height or height-for-age Z-score< -3; Appendix I)
Pre-existing severe hematological toxicity (temporary exclusion)
Blood transfusion within 60 days before enrollment (temporary
exclusion)
Hydroxyurea use within 6 months of study enrollment (temporary
exclusion)
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The inclusion criteria do not include factors related to clinical
severity, providing each site the liberty to choose those patients for
whom they think hydroxyurea would provide the most benefit,
regardless of clinical complications. Clinical staff will identify
eligible participants and discuss the study with the patient and
family in the appropriate local languages. Each site has established
its own recruitment and enrollment strategies, to maintain study
participants and ensure high-quality research data collection. These
strategies include the selection of families with a history of
excellent compliance with clinic follow-up, and families that live
within a reasonable distance from the hospital and are willing and
able to travel to the hospital for the frequent study visits.
Study treatment. After informed, written consent is obtained,
the participant will be officially enrolled in the study and begin
a 2-month evaluation period with screening studies. Once the
screening period is completed, trial participants will commence
open-label hydroxyurea treatment with three phases: fixed
dose (6 months), escalation to MTD (6 months), and a prolonged
maintenance phase (12–36 months) until the common study
termination date of 4 years from the first administered dose.
Figure 2 provides a summary of the treatment phases and
associated monitoring required throughout the study. Determina-
tion of hydroxyurea-related toxicity and treatment decisions
regarding hydroxyurea dosing and dose escalation will be
performed using the REACH dosing calculators available on
the study website (Supplementary Figure S1). The wide range of
available capsule sizes allows a single daily dose of hydroxyurea
for each patient.
Primary Study Endpoint
The primary objective of REACH is to determine whether
hydroxyurea therapy is safe for a large cohort of children with SCA
at different clinical sites in sub-Saharan Africa. Because each local
population will be different, based on a variety of criteria such as
tribal ethnicity, location, genetics, income and nutritional status,
each clinical site will be considered both independently and in
aggregate in analyses of study outcomes. Safety will primarily be
defined by the number of participants who experience early
hematological toxicity requiring temporary dose suspension or dose
modification, as defined in Table II.
Hematological toxicities and occasional dose adjustments or
medication holds are expected with hydroxyurea therapy. To
account for the lower baseline hemoglobin values for children with
SCA living in Africa,[37] the thresholds for hematological toxicity
aremodified from those used in North American studies. Some dose
adjustments will be due to drug-related toxicity, whereas others will
be sporadic cytopenias such as those occurring during infection,
especially in the setting of malaria and parvovirus. For comparison,
the BABY-HUG study reported toxicities of severe neutropenia in
5% of enrolled patients, whereas severe anemia occurred in 1% and
thrombocytopenia in 11%; importantly, however, hematological
toxicities were also noted in the placebo-treated arm.[25] Similarly,
the HUSOFT study reported severe neutropenia (21% of patients)
and severe anemia (25%), but that study had a smaller cohort than
BABY HUG, was open-label without a control arm, and had
slightly different toxicity thresholds.[26] Based on these data, in the
REACH sample size calculations, 20% of participants are expected
to have a dose-limiting hematological toxicity during the first
3 months of study treatment. However, given the potential for
cytopenia that is unrelated to hydroxyurea treatment, a threshold of
30% is selected for the highest acceptable percentage with a
hematological toxicity for the primary study endpoint.
Fig. 2. REACH Study and Treatment Phases. After obtaining informed
consent, participants will proceed through each of four phases of the
REACH study. Prior to initiation of hydroxyurea, there is a 2-month
screening phase, followed by 6-month fixed dose phase, 6 months of
dose escalation to maximum tolerated dose (MTD), and a maintenance
phase that will continue for all participants through the Common
Termination Date.
TABLE II. REACH Toxicity and Dose Escalation Criteria
Toxicity Parameter Escalation criteria Toxicity criteria
Neutropenia ANC ( 109/L) >4.0 <1.0
Anemia Hb (gm/dl) >6.5 Hb <4.0 or Hb <6.0 unless ARC >100
Reticulocytopenia ARC ( 109/L) >150 ARC <80 unless Hb >7.0
Thrombocytopenia Platelets ( 109/L) >150 <80
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Sample Size Calculations
Sample size was calculated using Simon’s two-stage procedure
with expected and unacceptable levels of toxicity set at 20% and
30%.[38] To achieve 90% power with a type I error rate of 10%, a
sample size of 133 is required for each site (53 for the first stage),
and to accommodate drop-outs and screening failures, a total of 150
enrollments will occur at each site. Using this two-stage approach,
the first analysis will occur after 53 participants at each site have
completed 3 months of hydroxyurea at the starting dose of 15–
20mg/kg/day, but will also include participants who experience a
dose-limiting hematological toxicity during the first 3 months. The
main advantage of this two-stage adaptive design is the ability to
identify an unsafe drug dose early in the study, thus allowing dose
modification and eventual determination of a safe hydroxyurea
dose. Figure 3 outlines the statistical design and time points at
which safety analyses will be performed.
Secondary Endpoints
The safe and effective use of hydroxyurea is highly dependent
on appropriate dosing and monitoring of therapy, in the setting of
excellent medication adherence for all research participants.
Monthly clinic visits with laboratory testing will be required
during the initial phases of REACH, as this frequency of monitoring
is the current standard of care in the United States. Adherence to
monthly clinic visits and successful completion of required
laboratory assessments will constitute the primary outcome
measures of feasibility. Adherence to hydroxyurea therapy will
also be determined using pill counts and the Modified Morisky
Scale.[39,40]
In addition to the primary safety analyses, there will be
additional analyses to assess the clinical and laboratory safety
of hydroxyurea for study participants. All Grade 2 or higher
adverse events will be collected prospectively and evaluated
carefully, particularly the infectious complications, which may
be frequent and severe in this susceptible study population. The
REACH study team includes a co-investigator in infectious
disease who developed guidelines for the evaluation and
management of febrile events and other infectious complica-
tions. To address the lack of a comparison group or placebo-
controlled cohort, the 2-month screening period will include
three scheduled visits before study treatment initiation, with
complete blood counts and collection of clinical events (e.g.,
fever, infections, transfusions).
Although REACH is not formally an efficacy trial, the benefits
of hydroxyurea will be assessed through HbF quantitation and other
hematological parameters, comparing treatment values with those
at baseline and during the pre-hydroxyurea screening period.
Clinical data including growth, number of vaso-occlusive pain
crises, acute chest syndrome, infections, transfusions, and hospital-
izations will also be captured as secondary outcomes to help
determine treatment-related benefits. Although pediatric sickle cell
deaths are rare in high resource settings, some are likely to occur
in the REACH study population. Each clinical site agreed to
standardize the documentation of all deaths among their patient
population (including patients enrolled and not enrolled in the
REACH study) using the WHO verbal autopsy form.[41]
Study Oversight
The REACH Data Safety and Monitoring Board (DSMB)
includes individuals with extensive expertise in SCA, hydroxyurea
therapy, infectious diseases, biostatistics, and global health.
Additionally, an external African Advisory Board has been named,
which includes national medical leaders from each African country
involved in the study. The charge of the African Advisory Board
will be to relay the research findings into meaningful policy within
their own Ministries of Health and public health systems.
DISCUSSION
To our knowledge, the REACH study is the first prospective
multicenter clinical trial involving hydroxyurea therapy for
children with SCA in sub-Saharan Africa. The protocol was
written and finalized with the full involvement and consensus of all
site leaders; this approach values African site autonomy, while also
providing a safe and ethical trial whose results will be meaningful.
Rather than imposing North American research goals, this
international partnership provides each clinical site with indepen-
dence and promotes capacity building through training of site
personnel in hydroxyurea use and high quality research. The
research team recognized the limitations of not including a control
or placebo comparison group, but felt unanimously that withhold-
ing effective treatment from patients, just for the sake of collecting
comparison data, was unethical. Despite the lack of a placebo-
treated group, the significance of collecting prospective data using
open-label hydroxyurea treatment cannot be overstated, as the
results could lead to wider use of the drug and integration of
Fig. 3. REACH Statistical Flowchart. The REACH study has an
adaptive, two-stage design allowing for early identification of hydroxy-
urea toxicity. The first stage will enroll 53 participants; if 15 or fewer
hematological toxicities occur, study enrollment can continue to reach
thefinal required number of133. If there aregreater that 15hematological
toxicities during this first stage, the starting dose will be reduced to 10–
15mg/kg/day and enrollment will begin again. In order to account for
participant drop-out, 60 participants will be enrolled in the first stage and
150 participants in the entire study at each site. This study algorithmwill
occur with independent analysis at each individual site.
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hydroxyurea treatment into national strategies for managing SCA.
Without proper data, underutilization of hydroxyurea in this setting
would likely ensue, depriving children of a potent, relatively
inexpensive, and readily available disease-modifying therapy to
prevent morbidity, disability, and mortality. However, its potential
overutilization or unsafe use without prospective data on proper
dosing or monitoring is equally problematic; hence the need for the
REACH study.
There are several unique aspects of the REACH trial that are
worth noting. First is the close partnership between investigators in
North America and Africa, who together wrote the final protocol
after discussion and consensus. The additional partnership between
academia and industry is also notable, as BMS is the main on-label
manufacturer of hydroxyurea and agreed to donate all hydroxyurea
needed for this important clinical trial. Second is the intentional
inclusion of four sites with geographically high burdens of SCA
across sub-Saharan Africa. Each site has a unique and diverse
patient population, which will be crucial for generalizing the
feasibility and safety of hydroxyurea treatment in different settings.
Although the hypothesis is that hydroxyurea will be equally safe
across sites, there may be important co-morbidities within a specific
population that results in increased toxicities from hydroxyurea
therapy. Third is the two-stage design of REACH, which allows for
early identification of safety concerns and lowers the hydroxyurea
dosing if the initial fixed dose of 15–20mg/kg/day results in an
unacceptable frequency of toxicities. Next is the internationally
accessible internet-based electronic data capture system (RED-
Cap), which will allow the timely entry of study data in several
different languages; the study website has been equipped with
software tools in three languages that allow easy and accurate
hydroxyurea dosing using web-based calculators. Finally, the
REACH study has expert and transparent oversight; in addition to
co-investigators who bring valued expertise, the multi-disciplinary
and international DSMB will provide expertise in safety and data
review, whereas the African Advisory Board will help translate the
research findings into clinical practice within each individual
country.
As Ministries of Health across sub-Saharan Africa begin to
address the large and growing burden of SCAwithin their individual
countries, the expense of such care must be addressed. The cost of
quality sickle cell care in an African setting has been previously
considered,[42] but this analysis did not include costs of
hydroxyurea treatment and monitoring. Hydroxyurea, a relatively
inexpensive medicine (<$1 USD per generic 500mg capsule), has
the potential to dramatically reduce the rising burden of SCA in sub-
Saharan Africa by reducing the frequency and severity of acute
complications (pain, acute anemia, neurologic complications) of
SCA. REACHwill provide an opportunity to examine the costs and
benefits of hydroxyurea in four unique African settings, with the
expectation that the costs of drug and monitoring will be
outweighed by savings in hospitalizations and treatment of clinical
complications.
Results from the prospective multicenter REACH trial could be
transformative, by providing vital data that can inform the safe and
effective introduction of hydroxyurea into different regions of
Africa. The study also will provide critical baseline data and
strengthen a Central African research consortium, which should
allowmore definitive follow-up studies investigating the efficacy of
hydroxyurea for specific clinical complications. The REACH trial
will have even further significance by providing training about the
use of hydroxyurea within the framework of local practice, thereby
providing the local capacity necessary to expand the safe use of
hydroxyurea in the future.
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